Copyright © 2022 StrategyHelix Inc. All Rights Reserved.
Global Human Genetics Market 2022
Human genetics is the scientific study of inherited human variation. Understanding genetic factors and genetic disorders is important in learning more about promoting health and preventing disease. Some genetic changes have been associated with an increased risk of having a child with a birth defect or developmental disability or developing diseases such as cancer or heart disease. According to a report by StrategyHelix, the global human genetics market is set to increase by US$ 51.5 billion during 2022-2028, growing at a CAGR of 15.3% during the forecast period.
The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for human genetics. The global human genetics market is segmented on the basis of application, test method, and region. On the basis of application, the global human genetics market has been segmented into diagnostic & treatment, preventive medicine, others. Among these, the diagnostic & treatment segment was accounted for the highest revenue generator in 2021. By test method, the global human genetics market has been segmented into carrier testing, karyotyping, next-generation sequencing (NGS), noninvasive prenatal testing (NIPT), pharmacogenomic testing, SEPT9 biomarker testing, thrombophilia testing, others. Geographically, the global human genetics market is segmented into Asia Pacific, Europe, North America, Rest of the World (RoW).
The global human genetics market is highly competitive. Key companies profiled in the report include Atrys Health S.A., Bode Cellmark Forensics Inc., Elabscience Biotechnology Inc., EUROFINS MEGALAB S.A., FULLGENOMICS S.L., GENinCode Plc, Genologica, LABORATORIO ECHEVARNE S.A., Myriad Genetics Inc., NIMGENETICS GENOMICA Y MEDICINA S.L., Sistemas Genomicos S.L., SYNLAB International GmbH.
The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the human genetics market to help drive informed decision making for industry executives, policy makers, academic, and analysts.
Application: diagnostic & treatment, preventive medicine, others
Test method: carrier testing, karyotyping, next-generation sequencing (NGS), noninvasive prenatal testing (NIPT), pharmacogenomic testing, SEPT9 biomarker testing, thrombophilia testing, others
Region: Asia Pacific, Europe, North America, Rest of the World (RoW)
Years considered: this report covers the period 2018 to 2028
Key Benefits for Stakeholders
– Get a comprehensive picture of the global human genetics market
– Pinpoint growth sectors and trends for investment
Table of Contents
Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. Human genetics market overview
Part 3. Market breakdown by application
– Diagnostic & treatment
– Preventive medicine
Part 4. Market breakdown by test method
– Carrier testing
– Next-generation sequencing (NGS)
– Noninvasive prenatal testing (NIPT)
– Pharmacogenomic testing
– SEPT9 biomarker testing
– Thrombophilia testing
Part 5. Market breakdown by region
– Asia Pacific
– North America
– Rest of the World (RoW)
Part 6. Key companies
– Atrys Health, S.A.
– Bode Cellmark Forensics, Inc.
– Elabscience Biotechnology Inc.
– EUROFINS MEGALAB S.A.
– FULLGENOMICS, S.L.
– GENinCode Plc
– LABORATORIO ECHEVARNE S.A.
– Myriad Genetics, Inc.
– NIMGENETICS GENOMICA Y MEDICINA, S.L.
– Sistemas Genomicos, S.L.
– SYNLAB International GmbH